Ascendis Pharma A-S
Price & Volume
Stats
See more52W Range | $150.89-$248.60 |
Market Cap | $14.8B |
Shares Short | 3M |
Financials
See moreRevenue (12 Mos) | $720.1M |
Revenue Growth (YoY) | 42.3% |
Gross Profit (12 Mos) | $625.2M |
Diluted EPS | -$4.40 |
News
See moreYahoo Finance • 4 days ago
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
Yahoo Finance • 4 days ago
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia
Yahoo Finance • 6 days ago
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
Yahoo Finance • 8 days ago
Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial
About
CEO | Mr. Jan Moller Mikkelsen |
CFO | Mr. Scott T. Smith |
Address | Tuborg Boulevard 12, Hellerup, Denmark, 2900 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 1,189 |
